Cartesian Therapeutics Inc Quick Ratio (RNAC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cartesian Therapeutics Inc   (NASDAQ: RNAC)

Cartesian Therapeutics Inc 's Quick Ratio

RNAC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 7.18 above Cartesian Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 145 other companies have achieved higher Quick Ratio than Cartesian Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 621, from total ranking in the first quarter 2026 at 671.

Explain Quick Ratio?
How much Cash & cash equivalents RNAC´s has?
What are RNAC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RNAC Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 67.67 % 6.31 % -34.99 % -35.52 % -53.07 %
Y / Y Cash & cash equivalent Change -7.93 % -34.25 % -41.14 % -34.59 % 83.8 %
Quick Ratio MRQ 7.18 7.44 8.38 10.39 13.08
RNAC's Total Ranking # 621 # 671 # 500 # 402 # 464
Seq. Current Liabilities Change 28.88 % 6.75 % 8.22 % 12.62 % -18.28 %
Seq. Cash & cash equivalent Change 24.41 % -5.19 % -12.72 % -10.57 % -11.15 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 146
Healthcare Sector # 230
Overall Market # 626


Quick Ratio Statistics
High Average Low
13.08 5.07 0.36
(Jun 30 2025)   (Jun 30 2019)




Financial Statements
Cartesian Therapeutics Inc 's Current Liabilities $ 21 Millions Visit RNAC's Balance sheet
Cartesian Therapeutics Inc 's Cash & cash equivalent $ 148 Millions Visit RNAC's Balance sheet
Source of RNAC's Sales Visit RNAC's Sales by Geography


Cumulative Cartesian Therapeutics Inc 's Quick Ratio

RNAC's Quick Ratio for the trailling 12 Months

RNAC Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -8.93 % -33.4 % -47.74 % -57.98 % -52.53 %
Y / Y Cash & cash equivalent TTM Growth -30.78 % -21.73 % -2.12 % 43.14 % 122.54 %
Quick Ratio TTM 8.2 9.62 10.88 10.88 10.78
Total Ranking TTM # 143 # 136 # 81 # 78 # 117
Seq. Current Liabilities TTM Growth 14.57 % 1.69 % -12.55 % -10.61 % -16.21 %
Seq. Cash & cash equivalent TTM Growth -2.32 % -10.14 % -12.55 % -9.81 % 10.45 %

Quick ratio ranking by company, industry and sector >> Back to RNAC Financial Strength Comparisons >> Go to Compare RNAC Quick Ratio to its Competitors

  News about Cartesian Therapeutics Inc Quick Ratio

Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing



In a recent announcement, Cartesian Therapeutics, a clinical-stage biotechnology company focusing on mRNA cell therapy for autoimmune diseases, revealed that it has entered into a securities purchase agreement for private investment in public equity (PIPE) financing. The company expects to generate approximately $130.0 million in gross proceeds from this financing, which is scheduled to conclude on or around July 3, 2024, subject to customary closing conditions. This infusion of funds is anticipated to further bolster the company s research and development efforts in the field of autoimmune diseases.
Key Facts:
1. Cartesian Therapeutics, Inc. (NASDAQ: RNAC) has secured a private investment in public equity (PIPE) financing, resulting in an estimated $130.0 million in gross proceeds.
2. The financing agreement is subject to customary closing conditions and is expected to conclude on or about July 3, 2024.
3. The funds raised through this financing will provide Cartesian Therapeutics with the necessary resources to advance its mRNA cell therapy for autoimmune diseases.
4. Cartesian Therapeutics seeks to pioneer innovative solutions that address the complex challenges associated with autoimmune conditions.
5. The company aims to leverage mRNA-based cell therapies to develop personalized treatment options for a wide range of autoimmune diseases.
6. Cartesian Therapeutics has demonstrated significant growth in cash and cash equivalents, which increased by 34.46% in the first quarter of 2024 compared to the previous quarter.
7. The company s current liabilities decreased during this period, leading to an improved quick ratio of 2.82, indicating a strong ability to meet short-term obligations.
8. While Cartesian Therapeutics ranks higher in quick ratio compared to the fourth quarter of 2023, it is important to note that 146 other companies within the industry have achieved higher quick ratios in the first quarter of 2024.
9. Looking at the trailing twelve months, Cartesian Therapeutics quick ratio dropped slightly to 2.41, still above the company s trailing twelve months average.
10. Comparative analysis reveals that other companies in the industry have achieved superior quick ratios over the past twelve months, resulting in Cartesian Therapeutics overall ranking declining from 1711 in the fourth quarter of 2023 to 2473.

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2026 to $20.55 millions, cumulative Quick Ratio decreased to 8.2 above the RNAC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Cartesian Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3371.

Explain Quick Ratio?
How much Cash & cash equivalents RNAC´s has?
What are RNAC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 416
Healthcare Sector # 847
Within the Market # 621


trailing twelve months Quick Ratio Statistics
High Average Low
10.88 4.14 0.69
(Dec 31 2025)   (Dec 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Scynexis Inc   19.69 $ 114.696  Millions$ 5.825  Millions
Q32 Bio Inc   19.68 $ 106.270  Millions$ 5.401  Millions
Damora Therapeutics Inc   19.62 $ 540.515  Millions$ 27.550  Millions
Kairos Pharma Ltd   19.12 $ 5.067  Millions$ 0.265  Millions
Minerva Neurosciences Inc   19.02 $ 75.267  Millions$ 3.958  Millions
Abcellera Biologics Inc   18.05 $ 960.143  Millions$ 53.189  Millions
Sellas Life Sciences Group Inc   17.29 $ 138.443  Millions$ 8.006  Millions
Whitehawk Therapeutics Inc   17.17 $ 190.000  Millions$ 11.069  Millions
Forte Biosciences Inc   17.12 $ 347.331  Millions$ 20.289  Millions
Ovid Therapeutics Inc   17.01 $ 169.769  Millions$ 9.980  Millions
Bioage Labs Inc   16.59 $ 318.745  Millions$ 19.217  Millions
Olema Pharmaceuticals Inc   16.48 $ 873.571  Millions$ 53.014  Millions
Erasca Inc   16.41 $ 610.496  Millions$ 37.200  Millions
Janux Therapeutics Inc   16.14 $ 970.913  Millions$ 60.152  Millions
Edgewise Therapeutics inc   15.86 $ 460.709  Millions$ 29.042  Millions
Corvus Pharmaceuticals Inc   15.74 $ 215.200  Millions$ 13.672  Millions
Telomir Pharmaceuticals Inc   15.55 $ 5.170  Millions$ 0.332  Millions
Rapport Therapeutics Inc   15.34 $ 436.077  Millions$ 28.424  Millions
Lb Pharmaceuticals Inc  15.32 $ 369.576  Millions$ 24.128  Millions
Anixa Biosciences Inc   15.09 $ 26.330  Millions$ 1.745  Millions
Siga Technologies Inc  14.99 $ 117.584  Millions$ 7.845  Millions
Vyne Therapeutics Inc   14.87 $ 22.925  Millions$ 1.542  Millions
Alto Neuroscience Inc   14.64 $ 243.733  Millions$ 16.652  Millions
Tenax Therapeutics Inc   14.62 $ 118.000  Millions$ 8.073  Millions
Jade Biosciences Inc   14.61 $ 461.205  Millions$ 31.570  Millions
Immunome Inc   14.56 $ 519.996  Millions$ 35.713  Millions
Sensei Biotherapeutics Inc   14.54 $ 186.441  Millions$ 12.824  Millions
Cytokinetics Incorporated  14.39 $ 2,610.415  Millions$ 181.429  Millions
Canton Strategic Holdings Inc   14.18 $ 37.242  Millions$ 2.626  Millions
An2 Therapeutics Inc   14.04 $ 78.387  Millions$ 5.585  Millions

Date modified: 2026-09-26T07:30:32+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.